Hello everyone,

I've taken another look at my portfolio. I currently have a mix of a solid All World (23%) foundation, a strong cash/gold reserve (28%) and some aggressive individual bets such as $IREN (-9,1 %)
$HIMS (-8,07 %) and $LMND (-3,87 %) and $BTC (-1,24 %) .

What I've been missing so far is the "strong midfield" - a component that is less risky than stock-picking but has more power than a standard European index.

My plan: I consistently shift profits from my individual stocks (as soon as they reach +100%) into the iShares MSCI Europe Momentum $IEFM (-0,12 %) . Target weighting: 12 %.

Why exactly this ETF?

Instead of investing in the EuroStoxx 50 $CSSX5E (-0,25 %) "old industrial dinosaurs", the momentum factor filters out the strongest players in Europe at the moment (e.g. $SIE (-0,9 %)
$SAP (+0,64 %)).

Regional diversification: My portfolio is very US and tech-heavy. With the momentum approach, I get the European elite on board, including Switzerland, the UK and Denmark (which are missing from the EuroStoxx!).

Automatic rebalancing: If trends shift (e.g. from pharma to defense or tech), the ETF adjusts every six months. I don't have to guess which sector will perform next.

The strategy: I use my "high-flyers" as a source. When stocks like $IREN (-9,1 %) or $GOOGL (+0,9 %) reach their targets, I withdraw the stake and park it in the momentum ETF. In this way, I reduce my individual stock risk, but remain offensive in terms of the potential return.

The only watchpoint: Since I $NOVO B (+0,66 %) and $ASML (-0,53 %) as individual stocks, I make sure that the total weighting of these stocks in the ETF does not become a lump (limit: max. 8% per stock).

What do you think of the move? Would it be better to invest broadly in the Stoxx 50 $CSSX5E (-0,25 %) or 600 $EXSA (-0,07 %) or does the momentum factor make more sense for a growth strategy? 📈

$PLTR (-2,21 %)
$GOOGL (+0,9 %)
$AMZN (+0,15 %)
$IDXX (-0,81 %)
$RMBS (-5,53 %)
$AMD (-4,77 %)
$PEP (+4,55 %)
$MRK (+2,81 %)
$ETN (-0,29 %)
$AMGN (+0,66 %)
$ADM (+1,53 %)
$PFE (+2,06 %)
$UBER (-0,98 %)
$LLY (+2,81 %)
$NOVO B (+0,66 %)
$BSX (+3,13 %)
$ABBV (+1,73 %)
$QCOM (+0,96 %)
$ARM (-1,93 %)
$ELF (+0,22 %)
$CCI (+1,01 %)
$IREN (-9,1 %)
$BMY (+1,54 %)
$MSTR (+5,33 %)
$RBLX (-11,9 %)
$TEAM (-0,38 %)
$EL (+1,04 %)
$SYM
$DIS (+1,95 %)
$PYPL (+0,11 %)
$CMG (+0,12 %)
$ALV (-0,22 %)
$LIN (+2,12 %)

Which figures do you pay particular attention to?

Hello everyone,

What do you think of this portfolio?

Are there any improvements? Do you have any suggestions?

Thank you

$VWRL (+0,09 %)

$WSML (-0,4 %)

$SAP (+0,64 %)

$NOVO B (+0,66 %)

$V (+0,03 %)
$DDOG (+1,95 %)

$NOVO B (+0,66 %) has left my portfolio again. It's a bit too uncertain for me at the moment, so I preferred to secure my small profit. One or two days earlier would have been better, of course, but what the heck. I could possibly imagine re-entering the market if they drop again after the figures. Otherwise the money will go into an ETF as invest and forget money.

As Novo has become by far my largest single share due to the additional purchases, I have sold about 1/3 of my position and shifted into Hims&Hers.

In doing so, I am taking some risk out of the Novo position and adding another strong growth stock to my portfolio.

In my view, this was a clear case of $INTC (-3,29 %) . Around 90% in 12 hours was ok. It will be similar on Wednesday at $ASML (-0,53 %) and on 04.02. at $NOVO B (+0,66 %) . However, go short on both beforehand, as the figures do not come after the close of trading. With $ASML (-0,53 %) I am already in.

happy wife, happy life. Just under 33% profit.

There are currently rumors that a new partnership could emerge following the dissolution of the partnership in summer 2025. This could involve $HIMS (-8,07 %) Wegovy and oral medication... from $NOVO B (+0,66 %) directly without generics.

This would of course be a very bullish signal.

Brief evidence why this could happen: Novo Nordisk has filed 140 lawsuits against compounders but none against Hims, which are extremely compounders (still...)

So I could well imagine this happening.

Nevertheless, I would adjust GLP-1 from the balance sheet/income statement without considering this business. For me, that would merely be a bonus.

The momentum is currently catastrophic and the CEO must finally come forward, we are waiting for Q4!

Nevertheless, as you know, I have been very bullish for a long time and have about 20% of my portfolio in Hims (at the ATH even with 30%),

Don't forget, as Bezos once said: The stock is not the business, P/E ratio of 3, growth of 50%, clean balance sheet that is constantly improving...

I remain invested and continue to watch Hims!